India presently represents 3-4% of global biosimilar production, second to China and aims to increase it significantly. With ...

Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...

Finally, the number of opportunities in the biosimilars space is very high — there are more than 300 biologics in the market, ...

The European Medicines Agency (EMA) could table proposals next year to relax requirements around the need for comparative ...

Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption ...

Alvotech's biosimilars aim to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes.

Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster ...

The Centers for Medicare & Medicaid Services is attempting to cover anti-obesity medications under Medicare Part D and ...

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) have been given an average rating of “Moderate Buy” by ...

“Biosimilars are clearly a new and big issue for us,” she said, introducing Westminster Health Form’s Biosimilars in the NHS – Commissioning, Development and Engagement with Clinicians and ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

We recently compiled a list of the 10 Oversold Healthcare Stocks To Invest In. In this article, we are going to take a look ...